Tag: Tuberculosis
Multidose BCG Protects Against COVID-19 in At-Risk Individuals
Efficacy of 92 percent found among at-risk COVID-19-unvaccinated individuals with type 1 diabetes
Among Persons With HIV, More Finish Short-Course TB Prophylaxis
Treatment completion 90.4 percent for three months of rifapentine-isoniazid versus 50.5 percent for six months of isoniazid
TB Outbreak May Be Linked to Bone Repair Product
Aziyo Biologics recalling 154 containers of the bone putty that includes human cells and is used in a range of orthopedic procedures
Four-Month Rifapentine Regimen With Moxifloxacin Noninferior for TB
Rifapentine-based regimen with moxifloxacin noninferior to six-month control regimen of rifampin, isoniazid, pyrazinamide, ethambutol
BCG Vaccination Linked to Lower SARS-CoV-2 Seroprevalence
Seroprevalence of anti-SARS-CoV-2 IgG lower for health care workers with history of BCG vaccination
Four Months of Rifampin Costs Less Than Nine Months Isoniazid
Health system use and costs higher for nine months of isoniazid in adults and children in all settings
CDC: Modest Decreases Seen in TB Cases, TB-Related Deaths
From 2017 to 2018, 2 and 5 percent declines seen in incident TB and TB-related deaths, respectively
Incidence of Tuberculosis High in Children Exposed to the Disease
Preventive therapy effective in most TB-infected children if given before development of active disease
Short-Course Rifamycin-Based Regimens Preferred for Latent TB
Shorter regimens favored over longer course of isoniazid monotherapy for latent TB infection
Recommendations Developed for Multidrug-Resistant Tuberculosis
Use of at least five drugs recommended for intensive-phase treatment, four drugs for continuation phase
